Transforming Translational Science and Education to benefit human health

$416,808UL1FY2012TRNIH

Rockefeller University, New York NY

Investigators

Linked publications, trials & patents

Paper 39696436 Paper 39150780 Paper 38986441 Paper 38405978 Paper 38175961 Paper 37258985 Paper 36889664 Paper 36630059 Paper 36454164 Paper 36432576 Paper 35985288 Paper 35752539 Paper 35585372 Paper 35378531 Paper 35368563 Paper 35342110 Paper 35258551 Paper 35113854 Paper 34669180 Paper 34183371 Paper 33409504 Paper 33284111 Paper 33172906 Paper 33049200 Paper 33007263 Paper 32844723 Paper 32820026 Paper 32695494 Paper 32668112 Paper 32640929 Paper 32602053 Paper 32346799 Paper 32281309 Paper 32163377 Paper 32092142 Paper 32035124 Paper 32034051 Paper 31994749 Paper 31940699 Paper 31519698 Paper 31291582 Paper 31216123 Paper 31040214 Paper 31031114 Paper 31024557 Paper 31023376 Paper 30991908 Paper 30945313 Paper 30778326 Paper 30735632 Paper 30578871 Paper 30578351 Paper 30429615 Paper 30422916 Paper 30349896 Paper 30256551 Paper 30255293 Paper 30244099 Paper 30176893 Paper 30127434 Paper 30038963 Paper 29969437 Paper 29965997 Paper 29946305 Paper 29882021 Paper 29798886 Paper 29716915 Paper 29697469 Paper 29683134 Paper 29589181 Paper 29562312 Paper 29535801 Paper 29502462 Paper 29484583 Paper 29474921 Paper 29449635 Paper 29411455 Paper 29382553 Paper 29296957 Paper 29237833 Paper 29125826 Paper 29093272 Paper 29083474 Paper 29073044 Paper 28784598 Paper 28783042 Paper 28737771 Paper 28654734 Paper 28649453 Paper 28630179 Paper 28606988 Paper 28488400 Paper 28446061 Paper 28414293 Paper 28388406 Paper 28297718 Paper 28285255 Paper 28235196 Paper 28230549 Paper 28168211

Abstract

DESCRIPTION (provided by applicant): Methillin resistant S. aureus (MRSA) was first identified in clinical specimen in 1961 - shortly after the introduction of the first beta-Iactamas resistant antibiotic - Celbenin - into clinical practice. The key component of this resistance mechanism - the mecA gene - encoding a protein with very low affinity to all beta-Iactam antibiotics - is not a native gene for S. aureus but has been acquired on multiple occasions from a ''foreign'' source in the form of chromosomal cassettes. MRSA clones have emerged as major causative agents of serious and often life-threatening infections in hospitals worldwide and beginning with the late 1990s MRSA also found its way into the community. The most widely spread epidemic clones of MRSA also acquired resistance traits to the great majority of antimicrobial agents and therapeutic options against such multidrug resistant strains have become reduced to less than a handful of agents. The primary motive of this grant proposal is to find novel intervention strategies against MRSA by exploring more closely the mechanism of beta-Iactam resistance. Critical clues for such novel strategies were observations made in the two collaborating laboratories. The research program will use a combination of genetic, biochemical and metabolomic approaches and will be divided into four Specific Aims. Aim 1 will use metabolomic approaches to identify the mechanisms by which a library of auxiliary mutants can reduce resistance level of an MRSA strain. Aim 2 will compare the very different resistance levels produced by subpopulations of heterogeneously resistant epidemic clones of MRSA. Aim 3 will use genome sequencing to identify determinants in the genetic background of S. aureus that control the level of resistance to oxacillin. Aim 4 will use five contemporary isolates of MRSA recovered in Yr 2011 in New York hospital

View original record on NIH RePORTER →